Anti-integrin αvβ6 autoantibody
Novel specific biomarker for ulcerative colitis (UC)
Features of anti-integrin αvβ6 autoantibody in UC
Frequently detected in sera from patients with UC, compared to control diseases.
The model of pathophysiological role in UC has been proposed.
Easily detected in blood. Stool sample is not required.
What is the Ulcerative Colitis (UC) ?
Inflammatory bowel disease causes erosions and ulcers on the mucosa of the colon. Symptoms are Diarrhea, bloody stools, abdominal pain.
Provided by Kyoto University
Anti-Integrin αvβ6 ELISA Kit (RUO) is a novel kit to provide a highly specific detection of anti-integrin αvβ6 autoantibody in human serum.
Biomarkers in IBD- Prevalence in UC and Stratification between UC and other intestinal diseases -
Potential pathophysiological role of anti-integrin αvβ6 autoantibody
Integrin αvβ6, a heterodimeric protein expressed in epithelial cell, is a receptor for fibronectin, extracellular matrix protein. The recent publications reported that the autoantibody against integrin αvβ6 was frequently detected in ulcerative colitis patients1-4). It has been reported that the anti-integrin αvβ6 autoantibody may induce epithelial cell damage as a potential pathogenic role of ulcerative colitis 1). (see the diagram below)
Anti-Integrin αvβ6 ELISA Kit is a kit to provide a highly specific detection of anti-integrin αvβ6 autoantibody in human serum.
Evidence for anti-intergrin αvβ6 autoantibody as the biomarker of ulcerative colitis
- Patients with ulcerative colitis had IgG autoantibodies against integrin αvβ6 1,2).
- Anti–integrin αvβ6 autoantibody titers correlated with ulcerative colitis disease activity 1).
- IgG from patients with ulcerative colitis bound to the integrin αvβ6 expressed on colonic epithelial cells to block integrin αvβ6–fibronectin binding 1).
- Anti-integrin αvβ6 autoantibodies were frequently detected in pediatric ulcerative colitis as well 3).
- Auto-reactive plasma cell clone targeting integrin αvβ6 were isolated from ulcerative colitis 4).
- Anti-Integrin αvβ6 autoantibodies were detected in sera, years before diagnosis of ulcerative colitis 5).
References
- T. Kuwada et al. Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021;160(7):2383-2394.e21.
- N. Rydell et al. Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med. 2022;11(7):1881.
- Y. Muramoto et al. Anti-Integrin αvβ6 Antibody as a Diagnostic Marker for Pediatric Patients With Ulcerative Colitis. Gastroenterology. 2022;163(4):1094-1097.e14.
- M. Uzzan et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022;28(4):766-779.
- A. E. Livanos et al. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. Gastroenterology. 2023;164(4):619-629.
Comment from the researcher published in ‘‘Nature’’
‘‘If we had a biomarker, we would be able to diagnose ulcerative colitis with more confidence. Colonoscopies take at least one day to complete and can cost up to $200. But if the new testing kit is available, it will take roughly only 15 minutes to draw a blood sample and provide an appropriate result at a reasonable cost. We hope that it will be used in hospitals and clinical practice in Japan within the next two years.” says Dr. Shiokawa *.
* A sharper diagnosis for ulcerative colitis. ADVERTISEMENT FEATURE produced by NATURE research custom media.
MBL has developed Anti-Integrin αvβ6 ELISA Kit (RUO) in collaboration with A university in Japan, who has identified anti-Integrin αvβ6 autoantibody in ulcerative colitis.
About MBL
MBL was founded in 1969 as the first manufacturer of antibodies in Japan. Using technology built on advances in immunology and molecular biology, MBL offers clinical diagnostics and research reagents designed for analysis of proteins and/or genes associated primarily with autoimmune disorders, cancer, gynecological diseases, and infectious diseases. In recent years MBL has also been actively developing biomarker reagents and companion diagnostics, taking advantage of our strength in immunological and gene detection techniques. MBL is a JSR Life Sciences company.